Picard Medical / SynCardia Highlight Total Artificial Heart on BTV Program Airing on FOX Business News
MWN-AI** Summary
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, recently announced that its groundbreaking product, the SynCardia Total Artificial Heart (STAH), will be featured on the upcoming BTV Business Television segment airing on FOX Business News on March 14, 2026. The STAH is the world's first total artificial heart to gain approval from both the U.S. FDA and Health Canada, designed specifically to replace the pumping function of a failing heart while patients wait for a transplant.
With over 2,100 successful implants worldwide, the STAH is recognized as the most widely used and studied artificial heart technology globally. By replacing both the left and right ventricles and all four heart valves, the device effectively restores circulation in patients suffering from severe biventricular heart failure, a condition that can lead to imminent death without mechanical support.
The segment will also showcase the company's ambition to develop a next-generation, fully implantable artificial heart. This advanced technology aims to enhance patient mobility and quality of life by eliminating the need for external pneumatic support systems.
Patrick N.J. Schnegelsberg, CEO of Picard Medical, emphasized the importance of raising awareness about advanced heart failure therapies, especially as the demand for mechanical circulatory support increases. He stated that the SynCardia Total Artificial Heart has already provided critical support for numerous patients around the globe and that the company is focused on improving future solutions.
BTV Business Television is known for spotlighting emerging companies and their innovations across various industries, and the segment on Picard Medical aims to enlighten investors about the potential of the STAH technology. Following the broadcast, the segment will be accessible online through BTV’s distribution channels. For further information about Picard Medical, interested parties can visit their website or the SEC's site for public filings.
MWN-AI** Analysis
As Picard Medical, Inc. (NYSE American: PMI) gears up for the BTV feature on FOX Business News, investors should closely monitor the stock as this exposure could catalyze interest in the company’s revolutionary SynCardia Total Artificial Heart (STAH). Currently, the STAH stands as a beacon of innovation in mechanical circulatory support, having facilitated over 2,100 implants globally, and recognized as the first artificial heart approved by both the FDA and Health Canada.
Given the rising prevalence of heart failure, which presents a significant market opportunity, the segment's focus on the STAH's impact on patient care and its functionality as a lifesaving measure during transplantation waiting periods is particularly timely. As CEO Patrick N.J. Schnegelsberg emphasized, raising awareness of advanced heart failure solutions is crucial. Investor sentiment may be influenced positively if the segment highlights the company’s commitment to continual innovation, including the development of a next-generation artificial heart designed to enhance patient mobility.
Investors should view this televised exposure as an opportunity to gauge the market's reception to Picard Medical's advancements. The inclusion of the company in a respected investment-focused program could enhance visibility and credibility among institutional and retail investors alike, potentially driving stock demand.
However, it is essential to recognize the inherent risks detailed in the company’s forward-looking statements. Investors must approach the stock with a balanced view of the company's growth potential against the backdrop of market and technology uncertainties that may affect future performance.
In summary, the upcoming broadcast presents a strategic moment for potential investors. Monitoring Picard Medical's stock post-segment could reveal trends that align with the growing momentum for innovative healthcare solutions in the cardiovascular domain, making it a compelling watch for advanced investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that the SynCardia Total Artificial Heart (“STAH”) will be featured in an upcoming segment on BTV Business Television airing on the FOX Business News on Saturday, March 14 at 5:00 p.m. EST.
The segment will highlight the Company artificial heart technology designed to replace the pumping function of a failing human heart during the time that a patient awaits transplantation.
With more than 2,100 implants performed worldwide, the STAH remains the most widely used and extensively studied artificial heart technology globally. The device is considered a “total” replacement since it replaces both left and right ventricles and all four heart valves, restoring circulation in patients with severe biventricular heart failure who are at risk of imminent death without mechanical circulatory support.
The segment will also highlight the Company’s development of a next-generation, fully implantable artificial heart platform designed to improve patient mobility and quality of life by eliminating external pneumatic drivers.
“We believe raising awareness of advanced heart failure therapies is increasingly important as the number of patients in need of mechanical circulatory support continues to grow,” said Patrick N.J. Schnegelsberg, Chief Executive Officer of Picard Medical. “The SynCardia Total Artificial Heart has supported more than 2,100 patients worldwide by replacing the pumping function of a failing heart and providing critical time for patients awaiting transplantation. We are also advancing the next generation of artificial heart technology designed to further improve patient mobility and quality of life.”
BTV – Business Television is a long running investment focused television program that profiles emerging companies and technologies across a range of industries. The program airs across major financial networks and digital platforms and provides companies with exposure to retail and institutional investor audiences.
The Picard Medical segment will also be available via replay through BTV’s online distribution channels following the broadcast: http://www.b-tv.com/post/picard-medical-advancing-total-artificial-heart-technology-btv-feature.
About BTV – Business Television / BTV The Agency
For 28 years, BTV – Business Television has been on the air as the go-to half-hour investment show for savvy investors, delivering exclusive on-location interviews and actionable insights with emerging companies, industry leaders, and market experts. Hosted by Taylor Thoen and Jessica Katrichak, BTV provides investors with direct access to executive teams and compelling investment opportunities not found anywhere else. BTV The Agency is a capital markets–focused B2B TV production and digital marketing agency serving publicly traded and financial companies. Through strategic content creation and extensive distribution across top-tier networks including Bloomberg, CNBC, FOX Business News, and leading financial platforms, the agency helps companies reach investors, advisors, and institutions—building brand credibility and driving national retail and institutional investor awareness.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to address the increasing demand for mechanical circulatory support as highlighted by the segment on BTV Business Television?
What advances in technology can we expect from Picard Medical Inc. PMI's next-generation fully implantable artificial heart platform?
Can you elaborate on the competitive advantages Picard Medical Inc. PMI has over other artificial heart technologies in the market?
What impact has the SynCardia Total Artificial Heart had on patient outcomes globally, and how does Picard Medical Inc. PMI plan to continue promoting this technology?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
0.79% G/L:
$1.27 Last:
125,663 Volume:
$1.29 Open:
